
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **November 11, 2015**

AKERS BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

New Jersey

(State or other jurisdiction
of incorporation)

333-190456

(Commission
File Number)

22-2983783

(IRS Employer
Identification No.)

**201 Grove Road
Thorofare, NJ 080086**

(Address of Principal Executive Offices)

(856) 848-2116

Registrant's telephone number, including area code

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment of Director

On November 11, 2015, at a special meeting of the Board of Directors of the Company (the “Board”), the Board appointed Dr. Raza Bokhari as director of the Company, effective immediately.

Dr. Raza Bokhari, age 48

Dr. Raza Bokhari, age 48, has over 24 years of experience in healthcare senior management. Previously, he has been involved in five companies, also in the healthcare sector, holding positions including Chairman, Chief Executive Officer (CEO), President and Chief Development Officer (CDO). From Jan 2001 through May 2007, Dr. Bokhari was President and CEO of Lakewood Pathology Associates Inc., a national provider of anatomic pathology and diagnostic services company. From April 2003 to May 2008, he was the President and CEO of Parkway Clinical Laboratories (PCL), a national clinical reference laboratory with a focus on serving pain management specialists, behavioral health providers, and anti-aging and wellness providers. Dr. Bokhari again joined PCL in May 2013 to present day and serves as the Chairman and CEO. From May 2008 to May 2009, Dr. Bokhari was the Chief Development officer of Rosetta Genomics (ROSG) a publicly traded, microRNA-based diagnostic testing company. He also serves as Vice Chairman of the World Affairs Council of Philadelphia and is a Trustee of the esteemed Foreign Policy Research Institute. He has previously served as Trustee of Franklin Institute. Dr. Bokhari has a Doctor of Medicine degree from University of Punjab, Rawalpindi Medical College, Pakistan and an Executive MBA from the Fox School of Business, Temple University in Philadelphia, PA.

In evaluating Dr. Bokhari’s experience, qualifications, attributes and skills in connection with his appointment to the Board, the Company took into account his extensive experience in the healthcare and medical diagnostic industries.

Family Relationships

Dr. Bokhari does not have any family relationships with a current officer or director of the Company.

Related Party Transactions

There are no related party transactions.

Item 9.01 Financial Statements and Exhibits.

(c) Exhibits

Exhibit No.	Description
99.1*	Press Release

**filed herewith*

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AKERS BIOSCIENCES, INC.

Date: November 16, 2015

By: /s/ Raymond F. Akers, Jr., PhD
Raymond F. Akers, Jr., PhD
Executive Chairman

Akers Biosciences Appoints Dr. Raza Bokhari as Non-executive Director

THOROFARE, N.J., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ:AKER) (AIM:AKR.L), (the "Company"), a medical device company focused on reducing the cost of healthcare through faster, easier diagnostics, is pleased to announce the appointment of Raza Bokhari M.D. as a Non-executive Director of the Company.

Dr. Bokhari has significant experience of working with life science and healthcare services companies in the US. He currently serves as the Managing Partner of RBx Capital LP, a private equity fund in formation focused on investing in all segments of the US laboratory testing market. Dr. Bokhari is also Chairman and CEO of Parkway Clinical Laboratories, a College of American Pathologists accredited national CLIA-certified clinical reference laboratory performing diagnostic testing procedures.

In 2001, Dr. Bokhari acquired Lakewood Pathology Associates. During his term as President and CEO, until 2007, Lakewood Pathology Associates grew revenues ten times, expanded its client base to 25 states and created over 100 new jobs in the South Jersey region. It was sold in 2006 to Chicago-based private equity fund, Water Street Healthcare Partners, and received a \$50 million equity commitment.

Dr. Bokhari has a Doctor of Medicine degree from the University of Punjab, Rawalpindi Medical College, Pakistan, and an Executive MBA from The Fox School of Business at Temple University, PA, where he now serves as Chairman of the Executive Advisory Committee. Dr. Bokhari is frequently retained as a consultant for due diligence by private equity and venture capital funds focused on investing in life science, biotechnology and healthcare services companies.

"Dr. Bokhari is a very highly respected individual within the US healthcare business community," said Raymond F. Akers, Jr. PhD, Co-founder and Executive Chairman. "We are delighted to welcome him to the board of Akers Bio. His expertise, particularly in the fields of laboratory testing and health and wellness diagnostics - a growing area of importance for Akers Bio - will be invaluable as we continue to accelerate the commercialization of the Company's rapid diagnostic assays," added Dr. Akers.

About Akers Biosciences, Inc.

Akers Biosciences develops, manufactures, and supplies rapid screening and testing products designed to deliver quicker and more cost-effective healthcare information to healthcare providers and consumers. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical product distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics.

Additional information on the Company and its products can be found at www.akersbio.com. Follow us on Twitter @AkersBio.

Cautionary Statement Regarding Forward Looking Statements

Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company's expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words "anticipate," "believe," "estimate," "upcoming," "plan," "target", "intend" and "expect" and similar expressions, as they relate to Akers Biosciences, Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company's actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.

CONTACT: For more information:

Akers Biosciences, Inc.

Raymond F. Akers, Jr. PhD
Executive Chairman of the Board
Tel. +1 856 848 8698

Taglich Brothers, Inc. (Investor Relations)

Chris Schreiber
Tel. +1 917 445 6207
cs@taglichbrothers.com

finnCap (UK Nominated Adviser and Broker)

Adrian Hargrave / Scott Mathieson (Corporate Finance)
Steve Norcross (Broking)
Tel. +44 (0)20 7220 0500

Vigo Communications (Public Relations)

Ben Simons / Fiona Henson
Tel. +44 (0)20 7016 9570
akers@vigocomms.com
